Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 20 de 83 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Corvol J-C, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques A-R, Bourdain F, Brandel J-P, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee P-C, Brice A, Vidailhet M, Elbaz A, for the DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91:e189-201. [Ref.ID 102695]
2.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
3. Cita con resumen
Anónimo. Targinact for restless legs syndrome. Drug Ther Bull 2016;54:42-5. [Ref.ID 100171]
4. Cita con resumen
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-3. [Ref.ID 98401]
5. Cita con resumen
Anónimo. Rotigotine transdermique dans les jambes sans repos: troubles compulsifs. Prescrire 2014;34:351. [Ref.ID 97561]
6. Cita con resumen
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-83. [Ref.ID 97495]
7.Tiene citas relacionadas
Chokroverty S. Therapeutic dilemma for restless legs syndrome. N Engl J Med 2014;370:667-8. [Ref.ID 97119]
8.Tiene citas relacionadas Cita con resumen
Allen RP, Chen CC, García-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp Ll, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014;370:621-31. [Ref.ID 97115]
9. Cita con resumen
Anónimo. Transport d'anions ou de cations organiques et interactions. Prescrire 2012;32:676-7. [Ref.ID 93662]
10. Cita con resumen
Anónimo. Pamplemousses: des interactions avec les médicaments. Prescrire 2012;32:674-9. [Ref.ID 93661]
11. Cita con resumen
Anónimo. Mirapex (pramipexole): drug safety communication - ongoing safety review, possible risk of heart failure . FDA U.S. Food and Drug Administration 2012:19 de septiembre. [Ref.ID 93023]
14.
Brennan KA, Genever RW. Managing Parkinson's disease during surgery. BMJ 2010;341:990-3. [Ref.ID 89620]
15. Cita con resumen
Anónimo. Syndrome des jambes sans repos d'origine médicamenteuse. Prescrire 2010;30:270-2. [Ref.ID 88321]
16.Enlace a cita original
Grosset DG, Macphee GJA, Nairn M, on behalf of the Guideline Development Group. Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines. BMJ 2010;340:206-9. [Ref.ID 87708]
18.Enlace a cita original
de la Fuente Honrubia C, García del Pozo J, de Abajo FJ. Utilización de antiparkinsonianos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-10. [Ref.ID 86457]
19.
Micallef J, Rey M, Eusebio A, Audebert C, Rouby F, Jouve E, Tardieu S, Blin O. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009;67:333-40. [Ref.ID 85816]
20.
Anónimo. Rotigotine et jambes sans repos. Le pire des agonistes dopaminergiques. Prescrire 2009;29:331. [Ref.ID 85781]
Seleccionar todas
 
 1 a 20 de 83 siguiente >>